Radiofrequency Ablation for Thyroid Cancer
(PTC-RFA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests radiofrequency ablation (RFA) to determine its safety and effectiveness in treating small, low-risk papillary thyroid cancer (PTC) without surgery. RFA uses heat from radio waves to destroy thyroid cancer cells. It is suitable for adults with PTC less than 2 cm who cannot or do not want surgery, or who are transitioning from observation to active treatment. Participants will undergo the procedure with ultrasound guidance and local anesthesia, followed by regular check-ups for up to a year. The trial aims to assess how well RFA controls cancer and improves quality of life compared to traditional methods. As an unphased trial, this study provides a unique opportunity to explore a non-surgical treatment option that could enhance quality of life.
What prior data suggests that radiofrequency ablation is safe for treating low-risk papillary thyroid cancer?
Research has shown that radiofrequency ablation (RFA) is generally safe for treating papillary thyroid cancer. One study found that RFA offers a less invasive option with fewer complications and a quicker recovery time compared to traditional surgery. Patients undergoing RFA rarely develop hypothyroidism, a condition where the thyroid doesn't produce enough hormones, potentially reducing the need for follow-up visits.
Another study demonstrated that RFA effectively makes tumors disappear and reduces their size, indicating that the procedure works well to shrink cancer with a low risk of side effects. Long-term results also support the safety of RFA, with no major complications expected years after treatment.
Overall, evidence indicates that RFA is a well-tolerated treatment for small, low-risk papillary thyroid cancer, offering a promising alternative to surgery.12345Why are researchers excited about this trial?
Unlike the standard treatment for low-risk papillary thyroid cancer, which typically involves surgery, Radiofrequency Ablation (RFA) offers a minimally invasive alternative. RFA uses an ultrasound-guided, percutaneous approach to target and destroy thyroid tumors with heat, while sparing surrounding healthy tissues. This procedure is performed on an outpatient basis and requires only local anesthesia with conscious sedation, potentially leading to a quicker recovery and fewer complications compared to traditional surgery. Researchers are excited about RFA because it provides a non-surgical option that could reduce the invasiveness of thyroid cancer treatment while maintaining effective outcomes.
What evidence suggests that radiofrequency ablation is effective for low-risk papillary thyroid cancer?
Research has shown that radiofrequency ablation (RFA) effectively treats small, early-stage papillary thyroid cancer (PTC). Approximately 94.3% of tumors disappear after RFA treatment. One study found that 79% of patients with small thyroid cancers had no remaining cancer after the procedure. The likelihood of cancer recurrence is very low, with only about 1.5% of patients experiencing tumor growth after RFA. This treatment typically results in fewer complications and allows for quicker recovery compared to traditional surgery. In this trial, all participants will undergo RFA as a single treatment arm, focusing on low-risk papillary thyroid cancer.24567
Who Is on the Research Team?
Sangeet Ghai, MD
Principal Investigator
University Health Network - Toronto General Hospital
Are You a Good Fit for This Trial?
This trial is for adults (18+) with small papillary thyroid cancer tumors (less than 2 cm) that have not spread. Participants must have confirmed diagnosis, tumors safely away from vital structures, and either cannot or do not want surgery. Pregnant individuals are excluded.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo ultrasound-guided radiofrequency ablation (RFA) for curative treatment of small low-risk papillary thyroid cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment, including clinical visits, neck ultrasounds, blood tests, voice assessments, and patient-reported outcome questionnaires
Biopsy Assessment
Ultrasound-guided biopsy of the ablation site to assess local cancer control
What Are the Treatments Tested in This Trial?
Interventions
- Radiofrequency Ablation
Trial Overview
The study tests radiofrequency ablation (RFA), a minimally invasive procedure using heat to destroy thyroid cancer tissue, as an alternative to surgery in people with low-risk papillary thyroid cancer. All participants receive RFA and are monitored for up to one year.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
This single study arm includes adult participants with biopsy-confirmed, low-risk papillary thyroid cancer (\<2 cm) who undergo curative-intent radiofrequency ablation (RFA) of the thyroid tumor. RFA is performed once, on an outpatient basis, using a percutaneous, ultrasound-guided approach with an internally cooled radiofrequency electrode. The procedure is carried out under local anesthesia with conscious sedation, using a standardized moving-shot technique, with hydrodissection as needed to protect adjacent structures. No study drugs are administered as part of this intervention. The RFA procedure is a one-time treatment, although repeat ablation may be considered if residual disease is identified during follow-up, based on clinical judgment and participant consent. All participants in this arm follow the same post-procedure monitoring and follow-up schedule, which includes clinical assessments, neck ultrasound, thyroid blood tests, voice evaluation, patient-reported outcome quest
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
Citations
Long-Term Outcomes of Radiofrequency Ablation in Patients ...
A meta-analysis of 15 such studies demonstrated an overall tumor progression rate of 1.5% with a mean follow-up of 33 months, and lymph node ...
Meta-analysis Therapeutic outcomes and safety of ...
The pooled results demonstrate that RFA is an effective treatment modality for small, early-stage PTC, with a high cumulative tumor disappearance rate (94.3 %) ...
Can You Treat Thyroid Cancer with RFA?
Recent clinical outcomes for RFA of thyroid cancer show promising outcomes, especially for small, low-risk papillary tumors. Ideal ...
Comparison of radiofrequency ablation and surgery for ...
Radiofrequency ablation for papillary thyroid microcarcinoma has the advantages of less trauma, fewer complications, faster recovery and higher quality of life.
Outcomes and Risk Factors of Radiofrequency Ablation for ...
This cohort study examines long-term outcomes of radiofrequency ablation for T1N0M0 papillary thyroid cancer and the risk factors associated
Ultrasound-guided radiofrequency ablation for the treatment of ...
Ultrasound-guided thermal ablation represents a safe and effective treatment alternative for patients with papillary thyroid carcinoma who are ineligible for or ...
Long-Term Outcomes of Radiofrequency Ablation in ...
Unlike surgical patients, those treated with RFA rarely develop hypothyroidism, potentially reducing their motivation for continued follow-up.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.